BE1116
BiologicalA single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.
Other names: 4F-PCC
NCT Number: NCT07094087
This is a phase 3, multicenter, randomized, open-label, parallel-group, controlled study to assess the efficacy and safety of BE1116 compared with fresh frozen plasma (FFP) in adult participants undergoing complex cardiovascular surgery with CPB. The primary purpose of the study is to compare the efficacy of BE1116 and FFP in correcting coagulation factor deficiencies in bleeding participants undergoing complex cardiovascular surgery with CPB.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 3
Kingston Health Science Center, Kingston, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.
Other names: 4F-PCC
A single dose of FFP will be administered as investigational product (IP) by IV infusion intraoperatively.
Time frame: At Day 1 after IP infusion (30 minutes after the end of infusion)
Successful correction ("yes" vs "no") of coagulation factor deficiency as measured by an international normalized ratio (INR) of less than or equal to (≤) 1.4 at 30 minutes after the end of IP infusion.
Time frame: Up to 24 hours after the end of IP infusion
The hemostatic response will be recorded as either effective or not effective. 'Effective' is defined as no hemostatic intervention was required, whereas 'non effective' is defined as a hemostatic intervention was required in the period from 30 minutes to 24 hours after the end of IP infusion. Hemostatic intervention includes surgical re-intervention for bleeding and / or the administration of any systemic hemostatic agents.
Time frame: At Day 1 after IP infusion (30 minutes after the end of infusion)
Successful correction ("Yes or No") of coagulation factor deficiency measured by a rotational thromboelastometry (ROTEM) extrinsically activated thromboelastometric test (EXTEM) clotting time (CT) ≤ 80 seconds or thromboelastography (TEG) reaction time ≤ 8 minutes. ROTEM and TEG are viscoelastic coagulation tests that quantify the process of clot formation and degradation.
Time frame: From baseline (before IP infusion), to 30 minutes, 6 hours, 24 hours, and 48 hours after the end IP infusion
Time frame: Up to 24 hours after the start of IP infusion
The hemostatic response will be recorded as either effective or not effective. 'Effective' is defined as no hemostatic intervention was required, whereas 'non effective' is defined as a hemostatic intervention was required in the period from the start of IP infusion to 24 hours after the start of IP infusion. Hemostatic intervention includes surgical re-intervention for bleeding and / or the administration of any systemic hemostatic agents.
Time frame: From baseline (before IP infusion) to 30 minutes and 24 hours after the end IP infusion
Measurements on either ROTEM EXTEM CT or TEG reaction time will be collected. To combine these measurements, z-scores will be calculated for each method of measurement. The z-score standardizes each measurement by subtracting the mean and dividing by the standard deviation of the respective method.
Time frame: From baseline (before IP infusion) to 30 minutes after end of IP infusion
The BSS is a validated intraoperative scale used in clinical studies of hemostatic agents as a measure of bleeding severity. Bleeding is scored on a scale from 0 (no bleeding) to 4 (unidentified or inaccessible spurting or gush). A lower score indicates a better outcome.
Time frame: During surgery (Day 1) and on the first postoperative day (Day 2)
Bleeding is assessed based on 9 events occurring during surgery or within the first postoperative day. These 9 events will be used to determine UDPB class ranging from Class 0 to 5 as follows: Class 0 (insignificant), Class 1 (mild), Class 2 (moderate), Class 3 (severe), and Class 4 (massive).
Time frame: From the start of IP infusion and up to 24 hours and 5 days after surgery
The ABPs include whole blood, cryoprecipitate, platelets, red blood cells (RBCs), and FFP (except the dose administered as IP). For the purposes of this study, a dose of fibrinogen concentrate will be counted as an ABP, because it is administered in lieu of cryoprecipitate.
Time frame: Up to 24 hours after the start of IP infusion
The ABPs include whole blood, cryoprecipitate, platelets, RBCs, and FFP (except the dose administered as IP). For the purposes of this study, a dose of fibrinogen concentrate will be counted as an ABP, because it is administered in lieu of cryoprecipitate.
Time frame: Up to 24 hours after the end of surgery
Time frame: Up to 30 days after surgery
Time frame: Up to 30 days after surgery
The duration of mechanical ventilation is defined as the number of days on mechanical ventilation after the study surgery. If there are multiple incidences of mechanical ventilation, the duration will be the sum of the number of days for all incidences.
Time frame: Up to 30 days after surgery
The duration of primary ICU stay is defined as the number of days in the ICU after the study surgery.
Time frame: Up to 30 days after surgery
The duration of primary hospital stay is defined as the duration in calendar days from the date of IP administration to the date of primary hospital discharge, or death in the hospital, or end of study (EOS) visit, whichever occurs first.
Time frame: Up to Day 1 during the primary hospital stay, and within 28 days following IP infusion
Time frame: Up to 30 days after IP infusion
Time frame: From baseline to 30 minutes after the end of IP infusion
Time frame: Up to 48 hours after the end of IP infusion
Contact information is provided by the study sponsor or research team.
CSL Behring
Industry
A Phase 3, Multicenter, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07393087
Cardiac Surgery Recovery, Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Lausanne, Canton of Vaud, Switzerland
View Trial Details